FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912258234> ?p ?o ?g. }

• W2912258234 endingPage "S211" @default.
• W2912258234 startingPage "S210" @default.
• W2912258234 abstract "IntroductionAllogeneic hematopoietic stem cell transplantation using UCB (UCBT) is an alternative approach for severe aplastic anemia (SAA) patients (pts) lacking an HLA matched donor. However, UCBT is associated with delayed engraftment, high graft failure and mortality rates. Ex-vivo expanded UCB using nicotinamide (NAM) can engraft in NOD/SCID mice, and in pts with hematological malignancies in pilot studies. Here we investigated whether NAM-expanded UCBT would accelerate engraftment and immune reconstitution in refractory SAA pts.MethodsEligible SAA pts with severe neutropenia who failed immunosuppressive therapy underwent a NAM-expanded UCBT at a single center in a phase II trial. Pts were conditioned with cyclophosphamide (60 mg/kg × 2), horse ATG (40 mg/kg × 4), fludarabine (25 mg/m2 × 5) and 200cGy of TBI. GVHD prophylaxis included tacrolimus and MMF. Cohort 1 is designed to transplant six pts with a single NAM-expanded unit combined with 3 × 106 CD34+ cells/kg from a haploidentical donor as a stem cell backup. Once adequate cord engraftment is established, Cohort 2 will transplant a NAM-expanded unit alone. Engraftment and immune recovery were assessed and compared with a conventional UCBT combined with haploCD34+ cells using the same conditioning and GVHD prophylaxis.ResultsFrom 2017 to 2018, two SAA pts (22 years male and 45 years female, pre-transplant ANC ≤300/uL, failed ATG/CSA/Eltrombopag) successfully underwent a single 6/8 HLA-matched NAM-expanded UCBT combined with haplo CD34+ cells. UCB units before expansion contained a median total nucleated cell (TNC) dose of 2.8 × 107/kg and 1.7 × 105 CD34+ cells /kg. At transplant, NAM-expanded units contained a median 6.0 × 107 TNCs/kg and 96.4 × 105 CD34+ cells /kg, representing a median TNC and CD34+ cell expansion of 2-fold and 52-fold, respectively. At 14 and 7 months post-transplant, both pts were GVHD-free and survived with stable engraftment and transfusion independence (Figure 1). The median time to neutrophil and platelet recovery was only 6.5 days (range 6-7) and 35.5 days (31-40), with >95% cord donor myeloid and T-cell chimerism occurring at days 6.5 and 23.5, respectively. Immune recovery was brisk (Figure 2): absolute CD4+ > 200 cells/μL occurred at 17 and 60 days; at day 100, mean CD4+ cells were 382/μL and IGA 92 mg/dL. Compared to 16 SAA pts who received a single unexpanded UCBT with haplo CD34+ cells at our institute from 2013 to 2016, engraftment and immune recovery were superior in SAA pts with NAM-expanded UCBT (P<0.05, Figures 1 and 3).ConclusionThese results show for the first time that NAM-expanded UCB results in rapid cord engraftment, sustained hematopoiesis and accelerated immune recovery in treatment refractory, neutropenic SAA pts. The high numbers of CD34+ progenitor cells in NAM-expanded grafts could potentially overcome graft failure which limits conventional UCBT for SAA." @default.
• W2912258234 created "2019-02-21" @default.
• W2912258234 creator A5000611897 @default.
• W2912258234 creator A5013999699 @default.
• W2912258234 creator A5019581164 @default.
• W2912258234 creator A5021539931 @default.
• W2912258234 creator A5037993782 @default.
• W2912258234 creator A5050466936 @default.
• W2912258234 creator A5051959420 @default.
• W2912258234 creator A5057847118 @default.
• W2912258234 creator A5059805179 @default.
• W2912258234 creator A5072166479 @default.
• W2912258234 creator A5076074380 @default.
• W2912258234 creator A5077082272 @default.
• W2912258234 creator A5083445600 @default.
• W2912258234 creator A5083742882 @default.
• W2912258234 creator A5086602479 @default.
• W2912258234 creator A5087705062 @default.
• W2912258234 creator A5090423342 @default.
• W2912258234 date "2019-03-01" @default.
• W2912258234 modified "2023-09-27" @default.
• W2912258234 title "Ex Vivo Nicotinamide-Expanded (NAM-Expanded) Unrelated Cord Bloodtransplantation (UCB) for Refractory Severe Aplastic Anemia Results in Rapid Engraftment and Expedites Immune Recovery" @default.
• W2912258234 doi "https://doi.org/10.1016/j.bbmt.2018.12.287" @default.
• W2912258234 hasPublicationYear "2019" @default.
• W2912258234 type Work @default.
• W2912258234 sameAs 2912258234 @default.
• W2912258234 citedByCount "3" @default.
• W2912258234 countsByYear W29122582342019 @default.
• W2912258234 countsByYear W29122582342021 @default.
• W2912258234 crossrefType "journal-article" @default.
• W2912258234 hasAuthorship W2912258234A5000611897 @default.
• W2912258234 hasAuthorship W2912258234A5013999699 @default.
• W2912258234 hasAuthorship W2912258234A5019581164 @default.
• W2912258234 hasAuthorship W2912258234A5021539931 @default.
• W2912258234 hasAuthorship W2912258234A5037993782 @default.
• W2912258234 hasAuthorship W2912258234A5050466936 @default.
• W2912258234 hasAuthorship W2912258234A5051959420 @default.
• W2912258234 hasAuthorship W2912258234A5057847118 @default.
• W2912258234 hasAuthorship W2912258234A5059805179 @default.
• W2912258234 hasAuthorship W2912258234A5072166479 @default.
• W2912258234 hasAuthorship W2912258234A5076074380 @default.
• W2912258234 hasAuthorship W2912258234A5077082272 @default.
• W2912258234 hasAuthorship W2912258234A5083445600 @default.
• W2912258234 hasAuthorship W2912258234A5083742882 @default.
• W2912258234 hasAuthorship W2912258234A5086602479 @default.
• W2912258234 hasAuthorship W2912258234A5087705062 @default.
• W2912258234 hasAuthorship W2912258234A5090423342 @default.
• W2912258234 hasBestOaLocation W29122582341 @default.
• W2912258234 hasConcept C126322002 @default.
• W2912258234 hasConcept C203014093 @default.
• W2912258234 hasConcept C2776694085 @default.
• W2912258234 hasConcept C2776755627 @default.
• W2912258234 hasConcept C2777063308 @default.
• W2912258234 hasConcept C2777408962 @default.
• W2912258234 hasConcept C2779263901 @default.
• W2912258234 hasConcept C2779972918 @default.
• W2912258234 hasConcept C2780007613 @default.
• W2912258234 hasConcept C2781440808 @default.
• W2912258234 hasConcept C2911091166 @default.
• W2912258234 hasConcept C29730261 @default.
• W2912258234 hasConcept C71924100 @default.
• W2912258234 hasConcept C90924648 @default.
• W2912258234 hasConceptScore W2912258234C126322002 @default.
• W2912258234 hasConceptScore W2912258234C203014093 @default.
• W2912258234 hasConceptScore W2912258234C2776694085 @default.
• W2912258234 hasConceptScore W2912258234C2776755627 @default.
• W2912258234 hasConceptScore W2912258234C2777063308 @default.
• W2912258234 hasConceptScore W2912258234C2777408962 @default.
• W2912258234 hasConceptScore W2912258234C2779263901 @default.
• W2912258234 hasConceptScore W2912258234C2779972918 @default.
• W2912258234 hasConceptScore W2912258234C2780007613 @default.
• W2912258234 hasConceptScore W2912258234C2781440808 @default.
• W2912258234 hasConceptScore W2912258234C2911091166 @default.
• W2912258234 hasConceptScore W2912258234C29730261 @default.
• W2912258234 hasConceptScore W2912258234C71924100 @default.
• W2912258234 hasConceptScore W2912258234C90924648 @default.
• W2912258234 hasIssue "3" @default.
• W2912258234 hasLocation W29122582341 @default.
• W2912258234 hasOpenAccess W2912258234 @default.
• W2912258234 hasPrimaryLocation W29122582341 @default.
• W2912258234 hasRelatedWork W2061000716 @default.
• W2912258234 hasRelatedWork W2075292277 @default.
• W2912258234 hasRelatedWork W2092542029 @default.
• W2912258234 hasRelatedWork W2274370047 @default.
• W2912258234 hasRelatedWork W2324403343 @default.
• W2912258234 hasRelatedWork W2346913724 @default.
• W2912258234 hasRelatedWork W2529570749 @default.
• W2912258234 hasRelatedWork W2560664961 @default.
• W2912258234 hasRelatedWork W3033238196 @default.
• W2912258234 hasRelatedWork W4385702570 @default.
• W2912258234 hasVolume "25" @default.
• W2912258234 isParatext "false" @default.
• W2912258234 isRetracted "false" @default.
• W2912258234 magId "2912258234" @default.
• W2912258234 workType "article" @default.